Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BOBoundless Bio, Inc. logo

Boundless Bio, Inc. (BOLD)

NASDAQ Global Select · Currency in USD
$2.36 ▼ -0.08 (-3.28%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.36 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$2.44
Open
$2.40
Day's Range
$2.36 – $2.41
52 Week Range
$0.96 – $3.16
Volume
34,870
Avg. Volume
1,008,512
Market Cap
$53.69M
Beta (5Y Monthly)
0.38
PE Ratio (TTM)
--
EPS (TTM)
-$2.85
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Boundless Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
28
CEO
Zachary Hornby

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.56
DateEst.Actual
Aug 4, 2026-$1.06-$1.06Beat
May 8, 2026-$0.51-$0.60Miss
Mar 9, 2026-$0.44-$0.58Miss
Nov 5, 2025-$0.53-$0.62Miss
Aug 5, 2025-$0.75-$0.70Beat
May 9, 2025-$0.68-$0.71Miss

Analyst view

Rating: Hold
Buy 30% · Hold 65% · Sell 5%

Get free alerts on BOLD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.